Irvine Scientific to exclusively distribute stem cell tech
Fujifilm Irvine Scientific said it has become the exclusive worldwide distributor of cellnest, a recombinant peptide attachment substrate that's designed to provide optimal adhesion and proliferation of stem cells for cell and gene therapy research. Read More
Stemedica's COVID-19 MSC therapy granted IND for clinical trial
Stemedica Cell Technologies received investigational new drug (IND) approval from the U.S. Food and Drug Administration for intravenous allogeneic mesenchymal stem cells (MSCs) in the treatment of moderate to severe COVID-19. Read More
Bioray Labs develops nonviral targeted CAR T therapy
Bioray Laboratories posted interim results from clinical trials of its nonviral programmed cell death 1 specific targeted chimeric antigen receptor (CAR) T therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Read More
Avrobio gets orphan drug nod for Gaucher disease gene therapy
Avrobio has been granted orphan drug designation for AVR-RD-02, an investigational gene therapy for treatment of Gaucher disease, by the European Commission. Read More
Is 'bespoke' therapy the future of genomic medicine?
Gene therapies hold extremely exciting promise for meeting the unmet needs of many individuals with genetic diseases, as discussed in a session of the second annual American Society of Gene & Cell Therapy Policy Summit on September 24. Read More
Amarna Therapeutics, FPS examine gene therapy platform
Amarna Therapeutics will collaborate with scientists from Progreso y Salud Foundation (FPS) of Spain to jointly examine the efficacy of Amarna's Svec gene delivery vector to develop effective immunotherapies for type 1 diabetes and multiple sclerosis. Read More
Neurophth's gene therapy granted orphan drug designation
Neurophth Therapeutics' lead candidate, NR082, an adeno-associated virus-based gene therapy, has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of Leber hereditary optic neuropathy associated with an ND4 mutation. Read More
Science serves society, a crucial concept for gene therapy governance
With a focus on science and society, the American Society of Gene & Cell Therapy Policy Summit commenced on September 24. The ensuing discussion revealed how far science has advanced in a short period of time, and how the scientific community is rising to the challenge of gaining public buy-in for gene therapy. Read More
Riffyn, Imperial College partner to speed up synthetic biology research
Riffyn and Imperial College in London have formed a partnership aimed at bringing Riffin's Nexus process data system to the public synthetic biology research community in the U.K. Read More
Thermo Fisher debuts clinical research grant program
Thermo Fisher Scientific introduced a clinical research grant program to support health projects in oncology and reproductive health. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter